In this open-label, non-randomized clinical study, we attempted to determine the feasibility of low-dose chemotherapy plus autologous dendritic cell vaccination [22] as a potential therapeutic option for angiosarcoma using canine HSA as a model system. Here, ALB is linked to angiosarcoma.